Literature DB >> 23575961

Respiratory syncytial virus--a comprehensive review.

Andrea T Borchers1, Christopher Chang, M Eric Gershwin, Laurel J Gershwin.   

Abstract

Respiratory syncytial virus (RSV) is amongst the most important pathogenic infections of childhood and is associated with significant morbidity and mortality. Although there have been extensive studies of epidemiology, clinical manifestations, diagnostic techniques, animal models and the immunobiology of infection, there is not yet a convincing and safe vaccine available. The major histopathologic characteristics of RSV infection are acute bronchiolitis, mucosal and submucosal edema, and luminal occlusion by cellular debris of sloughed epithelial cells mixed with macrophages, strands of fibrin, and some mucin. There is a single RSV serotype with two major antigenic subgroups, A and B. Strains of both subtypes often co-circulate, but usually one subtype predominates. In temperate climates, RSV infections reflect a distinct seasonality with onset in late fall or early winter. It is believed that most children will experience at least one RSV infection by the age of 2 years. There are several key animal models of RSV. These include a model in mice and, more importantly, a bovine model; the latter reflects distinct similarity to the human disease. Importantly, the prevalence of asthma is significantly higher amongst children who are hospitalized with RSV in infancy or early childhood. However, there have been only limited investigations of candidate genes that have the potential to explain this increase in susceptibility. An atopic predisposition appears to predispose to subsequent development of asthma and it is likely that subsequent development of asthma is secondary to the pathogenic inflammatory response involving cytokines, chemokines and their cognate receptors. Numerous approaches to the development of RSV vaccines are being evaluated, as are the use of newer antiviral agents to mitigate disease. There is also significant attention being placed on the potential impact of co-infection and defining the natural history of RSV. Clearly, more research is required to define the relationships between RSV bronchiolitis, other viral induced inflammatory responses, and asthma.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23575961      PMCID: PMC7090643          DOI: 10.1007/s12016-013-8368-9

Source DB:  PubMed          Journal:  Clin Rev Allergy Immunol        ISSN: 1080-0549            Impact factor:   8.667


  496 in total

1.  Interaction between asthma and lung function growth in early life.

Authors:  Hans Bisgaard; Signe M Jensen; Klaus Bønnelykke
Journal:  Am J Respir Crit Care Med       Date:  2012-03-29       Impact factor: 21.405

2.  Effect of chemokine receptor CX3CR1 deficiency in a murine model of respiratory syncytial virus infection.

Authors:  Crystal H Johnson; Congrong Miao; Elisabeth G Blanchard; Hayat Caidi; Gertrud U Radu; Jennifer L Harcourt; Lia M Haynes
Journal:  Comp Med       Date:  2012-02       Impact factor: 0.982

3.  Recurrent respiratory syncytial virus infections in allergen-sensitized mice lead to persistent airway inflammation and hyperresponsiveness.

Authors:  H Matsuse; A K Behera; M Kumar; H Rabb; R F Lockey; S S Mohapatra
Journal:  J Immunol       Date:  2000-06-15       Impact factor: 5.422

4.  Immunopathogenesis of respiratory syncytial virus bronchiolitis.

Authors:  Berkeley L Bennett; Roberto P Garofalo; Stanley G Cron; Yashoda M Hosakote; Robert L Atmar; Charles G Macias; Pedro A Piedra
Journal:  J Infect Dis       Date:  2007-04-12       Impact factor: 5.226

Review 5.  Pattern recognition receptors and genetic risk for rsv infection: value for clinical decision-making?

Authors:  Mika Rämet; Matti Korppi; Mikko Hallman
Journal:  Pediatr Pulmonol       Date:  2010-10-20

6.  Alteration of airway neuropeptide expression and development of airway hyperresponsiveness following respiratory syncytial virus infection.

Authors:  Azzeddine Dakhama; Jung-Won Park; Christian Taube; Mohamed El Gazzar; Taku Kodama; Nobuaki Miyahara; Katsuyuki Takeda; Arihiko Kanehiro; Annette Balhorn; Anthony Joetham; Joan E Loader; Gary L Larsen; Erwin W Gelfand
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2004-12-17       Impact factor: 5.464

7.  Macrophage impairment underlies airway occlusion in primary respiratory syncytial virus bronchiolitis.

Authors:  Jennifer L Reed; Yambasu A Brewah; Tracy Delaney; Timothy Welliver; Timothy Burwell; Ebony Benjamin; Ellen Kuta; Alexander Kozhich; LuAnn McKinney; JoAnn Suzich; Peter A Kiener; Luis Avendano; Luis Velozo; Alison Humbles; Robert C Welliver; Anthony J Coyle
Journal:  J Infect Dis       Date:  2008-12-15       Impact factor: 5.226

8.  Transmission of surfactant protein variants and haplotypes in children hospitalized with respiratory syncytial virus.

Authors:  Neal J Thomas; Susan DiAngelo; Joseph C Hess; Ruzong Fan; Margaret W Ball; Joseph M Geskey; Douglas F Willson; Joanna Floros
Journal:  Pediatr Res       Date:  2009-07       Impact factor: 3.756

9.  Immunoglobulin-class-specific immune response to respiratory syncytial virus structural proteins in infants, children, and adults.

Authors:  T Popow-Kraupp; E Lakits; G Kellner; C Kunz
Journal:  J Med Virol       Date:  1989-03       Impact factor: 2.327

10.  Nerve growth factor and nerve growth factor receptors in respiratory syncytial virus-infected lungs.

Authors:  Chengping Hu; Katrin Wedde-Beer; Alexander Auais; Maria M Rodriguez; Giovanni Piedimonte
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2002-08       Impact factor: 5.464

View more
  178 in total

1.  The challenge of treating orphan disease.

Authors:  Carlos Dias; Carlo Selmi
Journal:  Clin Rev Allergy Immunol       Date:  2014-12       Impact factor: 8.667

2.  Sirtuin 1 Regulates Dendritic Cell Activation and Autophagy during Respiratory Syncytial Virus-Induced Immune Responses.

Authors:  Anna B Owczarczyk; Matthew A Schaller; Michelle Reed; Andrew J Rasky; David B Lombard; Nicholas W Lukacs
Journal:  J Immunol       Date:  2015-07-08       Impact factor: 5.422

3.  Antibody-Induced Internalization of the Human Respiratory Syncytial Virus Fusion Protein.

Authors:  A Leemans; M De Schryver; W Van der Gucht; A Heykers; I Pintelon; A L Hotard; M L Moore; J A Melero; J S McLellan; B S Graham; L Broadbent; U F Power; G Caljon; P Cos; L Maes; P Delputte
Journal:  J Virol       Date:  2017-06-26       Impact factor: 5.103

4.  NK cells contribute to persistent airway inflammation and AHR during the later stage of RSV infection in mice.

Authors:  Xiaoru Long; Jun Xie; Keting Zhao; Wei Li; Wei Tang; Sisi Chen; Na Zang; Luo Ren; Yu Deng; Xiaohong Xie; Lijia Wang; Zhou Fu; Enmei Liu
Journal:  Med Microbiol Immunol       Date:  2016-06-21       Impact factor: 3.402

Review 5.  Persistent RNA virus infections: do PAMPS drive chronic disease?

Authors:  Mary K McCarthy; Thomas E Morrison
Journal:  Curr Opin Virol       Date:  2017-02-17       Impact factor: 7.090

6.  Discovery of Piperazinylquinoline Derivatives as Novel Respiratory Syncytial Virus Fusion Inhibitors.

Authors:  Xiufang Zheng; Lisha Wang; Baoxia Wang; Kun Miao; Kunlun Xiang; Song Feng; Lu Gao; Hong C Shen; Hongying Yun
Journal:  ACS Med Chem Lett       Date:  2016-04-20       Impact factor: 4.345

7.  Accelerated Discovery of Potent Fusion Inhibitors for Respiratory Syncytial Virus.

Authors:  Nicole Pribut; Thomas M Kaiser; Robert J Wilson; Edgars Jecs; Zackery W Dentmon; Stephen C Pelly; Savita Sharma; Perry W Bartsch; Pieter B Burger; Soyon S Hwang; Thalia Le; Julien Sourimant; Jeong-Joong Yoon; Richard K Plemper; Dennis C Liotta
Journal:  ACS Infect Dis       Date:  2020-04-20       Impact factor: 5.084

8.  Characterization of a respiratory syncytial virus L protein inhibitor.

Authors:  Choi-Lai Tiong-Yip; Lisa Aschenbrenner; Kenneth D Johnson; Robert E McLaughlin; Jun Fan; SreeRupa Challa; Hui Xiong; Qin Yu
Journal:  Antimicrob Agents Chemother       Date:  2014-04-28       Impact factor: 5.191

9.  Predictors and incidence of hospitalization due to respiratory syncytial virus (RSV)-associated lower respiratory tract infection (LRTI) in non-prophylaxed moderate-to-late preterm infants in Bosnia and Herzegovina.

Authors:  Hajrija Maksić; Suada Heljić; Fahrija Skokić; Darinka Šumanović-Glamuzina; Veroslava Milošević; Almir Zlatanović; Notario Gerard
Journal:  Bosn J Basic Med Sci       Date:  2018-08-01       Impact factor: 3.363

10.  Respiratory syncytial virus seropositivity at birth is associated with adverse neonatal respiratory outcomes.

Authors:  Sara Manti; Frank Esper; Marilyn Alejandro-Rodriguez; Salvatore Leonardi; Pasqua Betta; Caterina Cuppari; Angela Lanzafame; Sarah Worley; Carmelo Salpietro; Miriam K Perez; Fariba Rezaee; Giovanni Piedimonte
Journal:  Pediatr Pulmonol       Date:  2020-08-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.